Limited Coverage Drugs – risedronate
Special Authority requests can now be submitted online. It's simple and quick!
Learn more or log in
| Generic name | Strength, form | Special Authority criteria | Approval period |
|---|---|---|---|
| risedronate | 5 mg tablet or 35 mg tablet |
Clinical or radiographically documented fracture due to osteoporosis OR Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg or more of prednisone per day for 90 or more consecutive days |
Indefinite
1 year |
| risedronate | 30 mg | Diagnosis of Paget's disease | Indefinite |
Practitioner exemptions
- None
Special notes
- Patients who meet the above criteria for osteoporosis for risedronate automatically receive coverage for both alendronate and risedronate.
- Clinical fracture is defined as a symptomatic (painful) fracture.
- Radiographically documented fracture is defined as a fracture identified by x-ray (e.g., vertebral compression fracture). This may be asymptomatic.
- Coverage is intended for patients taking glucocorticoids with significant systemic absorption only (i.e., by oral or parenteral routes).
Special Authority requests
